Entities / Company
Kras.
Company
- Reports this week
- 0
- Active events
- 0
- Connections
- 16
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
Philadelphia is a major US city as the US invests in fundamental science research focused on KRAS, leveraging institutions like the University of Pennsylvania.Some support2 reports1 development inside
-
FDA approved Rasonque for metastatic PDAC, while Kras and Incyte also developed PDAC inhibitors and Incyte received a CMS settlement benefit.Some support2 reports
Gone quiet
No new reports in 90+ days-
Kras announced a significant milestone in its growth strategy, involving its expansion and partnership with Walmart.Some support1 report
-
A KRAS drug has demonstrated superior results compared to rivals in a lung cancer clinical trial.Some support1 report
-
Silexion Therapeutics Corp. pioneers RNAi therapies for KRAS-driven cancers, establishing partnerships with AMS and Catalent.Some support5 reports
No events began in the chosen period. Widen it, or reset.
Around Kras this week
News at the entities that move Kras most-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves Kras
-
Walmart OperationalPompeian oil is now available exclusively at Walmart stores.Moves Kras
-
Hoffmann-La Roche OperationalOmar Khwaja, a Fellow of the Royal College of Physicians, leads clinical research at Cancer Research UK.Moves Kras
Connections
The 5 strongest of 16, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Kalyani Group Structural
Kras and Kalyani Group are linked through a joint venture arrangement.
-
FDA Structural
FDA formally regulates and approves treatments targeting KRAS, dictating market viability for companies in this sector.
-
Hoffmann-La Roche Operational
The two companies are operating in the same competitive market, specifically in lung cancer trials.
-
Walmart Operational
The relationship is currently characterized by operational co-existence, noted as a strategic growth milestone.
-
Incyte Operational
Both companies are actively competing in the development of inhibitors for PDAC.
History
Events by the month they beganAugust 2026
1 eventJuly 2026
3 events- Philadelphia is a major US city as the US invests in fundamental science research focused on KRAS, leveraging institutions like the University of Pennsylvania.
- Kras announced a significant milestone in its growth strategy, involving its expansion and partnership with Walmart.
- A KRAS drug has demonstrated superior results compared to rivals in a lung cancer clinical trial.